Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
[forminator_form id="25163"]

novonordisk.com+1.jamanetwork.com+1.diario.mx+1.Novo Nordisk's Wegovy helped children as young as 6 lose weight in a two-year trial, adding to evidence that GLP-1 drugs work in younger patients. The results also raised new questions about how these drugs affect a growing child. The STEP Young results were presented at ObesityWeek 2026 on Monday, November 16, and published at the same time in The New England Journal of Medicine. They came a day after a separate trial showed that Eli Lilly's Zepbound worked in teenagers, The Wall Street Journal News Corp reported.novonordisk.com+1
The trial enrolled 167 children aged 6 to 11 with obesity. Their average age was 10, and at least 30% had severe obesity. Children were assigned at random to weekly semaglutide or a placebo, and both groups got lifestyle counseling, according to Healio. At 68 weeks, BMI fell 13.5% in the semaglutide group and rose 2.7% in the placebo group. Among children on the drug, 78.7% cut their BMI by at least 10%, and 38% dropped below the obesity threshold, compared with 2% on placebo, Healio reported. Novo's own analysis, which assumes children kept taking the drug, put the BMI drop at 17.4%, Pharmaphorum noted.healio.com+1
Stomach-related side effects were common: 70% of treated children vomited, compared with 29% on placebo. Researchers said they saw no new safety signals, according to Healio. However, children on semaglutide grew about 3.3 centimeters less than those on placebo, The New York Times reported. Antje Körner of the University of Leipzig told the conference that children with obesity tend to grow faster than their peers, and that the team "did not see any effects on puberty progression, puberty development or bone mineral density," Healio reported. Novo plans to ask the FDA to approve the drug for this age group. Wegovy is already approved for children 12 and older, according to the Times.diario.mx+1
Lilly's SURMOUNT-ADOLESCENTS trial included 160 patients aged 12 to 17. At 72 weeks, BMI fell an average of 18.5% with tirzepatide and rose 0.5% with placebo, according to the study published in JAMA. On average, teens lost about 40 pounds, Bloomberg reported. Zepbound is not yet approved for children, Pharmaphorum noted.jamanetwork.com+2
The World Health Organization's October guidelines advise against obesity drugs for children 9 and younger, Emory pediatric endocrinologist Daniel Hsia said, according to Healio. The American Academy of Pediatrics allows doctors to consider the drugs from age 8. It also remains unclear whether the weight loss lasts: children's BMI began rising again during a seven-week break from the drug, Yale's Ania Jastreboff said.healio.com
"It's not a question of whether it works, of course it works. But is it the right thing?" Robert Lustig of the University of California, San Francisco, told the Times.diario.mx